Biotech
FORT COLLINS, CO: Demonstrates Reduced Inflammation in Patients With Acute ST-Elevation Myocardial Infarction (STEMI)
...
FORT COLLINS, CO: Achieves Critical Manufacturing Milestone for Production of AAT-Fc Engages Destum Partners, Inc. to Advise on Business Development Initiatives
...
SOUTH SAN FRANCISCO, CA: 64% of Patients Achieved Stable Disease or Tumor Shrinkage on Combination Therapy Following Progression on Single-Agent Bevacizumab; U.S. FDA Set to Fund Phase 2 Investigator-Sponsored Trial
...
CEDAR KNOLLS, NJ: Third Quarter Marked by Positive, Statistically Significant Clinical Safety and Efficacy Data for Fortetropin(TM) Fueling Development of MYOS-Branded Proprietary Product Line; Company Plans to Impleme ...
EDMONTON, ALBERTA: - Company delivers strongest quarterly financial performance in its history - - Further increased revenue generation and market expansion expected in 2015 -
...
LAVAL, QUEBEC: - 2014 year-to-date product sales $7.3 million compared to $6.8 million in 2013 - H2 2014 revenue guidance range of $15 million to $20 million reiterated - Plasminogen and PBI-4050 cleared by regulato ...
